Mariela Blum Murphy, M.D.

Peer-Reviewed Articles

1. Sewastjanow-Silva M, Xiao L, Abdelhakeem A, Pabon CM, Yamashita K, Yoshimura K, Badgwell BD, Ikoma N, Meyer L, Sagebiel T, Das P, Li JJ, Ajani JA, Blum-Murphy MA. Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma. J Clin Oncol 43(21):2361-2371, 2025. e-Pub 2025. PMID: 40446172.
2. Badgwell, BD, Ikoma, N, Blum Murphy, M, Wang, X, Estrella, JS, Liu, X, Kawedia, J, Li, JJ, Mansfield, PF, Ajani, JA. Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology. Cancer 131(1), 2025. e-Pub 2025. PMID: 39287936.
3. Bhutiani N, Seo YD, Robinson KA, White MG, Ikoma N, Mansfield PF, Li JJ, Murphy MB, Ajani JA, Badgwell BD. HIPEC for metastatic gastric cancer: Moving the needle towards 3-year survival. Eur J Surg Oncol 51(1):108790, 2024. e-Pub 2024. PMID: 39489042.
4. Song Y, Hirata Y, Ajani JA, Blum Murphy M, Li JJ, Das P, Minsky BD, Mansfield PF, Ikoma N, Badgwell BD. ASO Visual Abstract: Survival Outcomes for Patients Who Have Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol 31(13):9063-9064, 2024. e-Pub 2024. PMID: 39402317.
5. Badgwell B, Ikoma N, Murphy MB, Li J, Wang X, Minsky BD, Estrella J, Mansfield P, Ajani J, Das P. Phase I Trial of Total Neoadjuvant Therapy with Short Course Chemoradiotherapy followed by Chemotherapy for Patients with Potentially Resectable Gastric Cancer. Int J Radiat Oncol Biol Phys, 2024. e-Pub 2024. PMID: 39237045.
6. Song Y, Hirata Y, Ajani JA, Blum Murphy M, Li JJ, Das P, Minsky BD, Mansfield PF, Ikoma N, Badgwell BD. Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol 31(10):6918-6930, 2024. e-Pub 2024. PMID: 39048909.
7. Sewastjanow-Silva M, Kwiatkowski E, Yamashita K, Abdelhakeem A, Yoshimura K, Vicentini ER, Pizzi MP, Jin J, Fan Y, Zou G, Wang L, Yin F, Dhar SS, Blum Murphy M, Mares JE, Li JJ, Gan Q, Waters RE, Rogers JE, Ajani JA. Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience. Int J Cancer 155(12):2277-2286, 2024. e-Pub 2024. PMID: 38995150.
8. Pabon CM, Yeboa DN, O'Brien BJ, Majd NK, Wang C, Blum Murphy MA. Intrathecal topotecan with systemic checkpoint inhibitor therapy for gastroesophageal cancer with leptomeningeal involvement: two case reports and review of the literature. J Gastrointest Oncol 15(3):1331-1340, 2024. e-Pub 2024. PMID: 38989402.
9. Badgwell B, Estrella J, Roy-Chowdhuri S, Ikoma N, Blum Murphy M, Ajani J, Mansfield P. Updated Analysis of a Phase 2 Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Peritoneal Carcinoma from Gastric Cancer. Ann Surg Oncol 31(5):2824-2825, 2024. e-Pub 2024. PMID: 38286882.
10. Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Blum Murphy M, Amaya-Chanaga C, Patel A, Hu N, Matsumura Y, Kitagawa Y, Ajani J. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med 13(9):e7235, 2024. e-Pub 2024. PMID: 38716626.
11. Abana CO, Damen PJ, van Rossum PS, Bravo PL, Wei X, Pollard-Larkin JM, Nitsch PL, Murphy MB, Hofstetter WL, Liao Z, Lin SH. Esophageal Cancer Outcomes After Definitive Chemotherapy With Intensity Modulated Proton Therapy. Int J Part Ther 11:100009, 2024. e-Pub 2024. PMID: 38757075.
12. Damen PJJ, van Rossum PSN, Chen Y, Abana CO, Liao Z, Hobbs BP, Mohan R, Blum-Murphy M, Hofstetter WL, Lin SH. Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer. Int J Part Ther 11:100012, 2024. e-Pub 2024. PMID: 38757082.
13. Sewastjanow-Silva M, Xiao L, Gonzalez GN, Wang X, Hofstetter W, Swisher S, Mehran R, Sepesi B, Bhutani MS, Weston B, Coronel E, Waters RE, Rogers JE, Smith J, Lyons L, Reilly N, Yao JC, Ajani JA, Murphy MB. Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study. Cancers (Basel) 16(7), 2024. e-Pub 2024. PMID: 38611056.
14. Yamashita K, Sewastjanow-Silva M, Yoshimura K, Rogers JE, Rosa Vicentini E, Pool Pizzi M, Fan Y, Zou G, Li JJ, Blum Murphy M, Gan Q, Waters RE, Wang L, Ajani JA. SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel. Cancers (Basel) 16(7), 2024. e-Pub 2024. PMID: 38610978.
15. Hirata Y, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum Murphy M, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma. Cancers (Basel) 15(21), 2023. e-Pub 2023. PMID: 37958312.
16. Hirata Y, Agnes A, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol 30(8):4936-4945, 2023. e-Pub 2023. PMID: 37106276.
17. Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, Tsimberidou AM, Kawedia JD, Fu S, Pant S, Yap TA, Morris VK, Kee BK, Blum Murphy M, Lim J, Meric-Bernstam F. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol 92(2):107-118, 2023. e-Pub 2023. PMID: 37314501.
18. Hirata, Y, Agnes, A, Estrella, JS, Blum Murphy, M, Das, P, Minsky, B, Ajani, JA, Badgwell, BD, Mansfield, PF, Ikoma, N. ASO Visual Abstract. Annals of surgical oncology 30(8):4948-4949, 2023. e-Pub 2023. PMID: 37193894.
19. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol 41(12):JCO2201351, 2023. e-Pub 2023. PMID: 36623241.
20. Vassilakopoulou M, Chen HC, Wang X, Harada K, Iwatsuki M, Das P, Blum Murphy M, Matamoros A, Sagebiel T, Devine C, Thomas I, Sanders EM, Shanbhag N, Rogers JE, Lee JH, Weston B, Bhutani MS, Hofstetter W, Nguyen QN, Badgwell BD, Ajani JA. Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment?. Oncology 101(3):153-158, 2023. e-Pub 2023. PMID: 36412619.
21. Zhou N, Hofstetter WL, Working Group ESCC, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg 114(6):2032-2040, 2022. e-Pub 2022. PMID: 34883083.
22. Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS high CD4 T cell populations and predictors of response. Clin Cancer Res 28(17):3695-3708, 2022. e-Pub 2022. PMID: 35511938.
23. Ahmed Abdelhakeem MD, Mariela Blum Murphy MD. Adjuvant Therapies for Esophageal Cancer. Thoracic Surgery Clinics 32(4):457-465, 2022. e-Pub 2022.
24. Abu-Sbeih H, Szafron D, Elkafrawy AA, Garcia-Rodriguez V, Ma W, Xu A, Khurana S, Numan L, Chen E, Goldstein R, Tsen A, Peng Y, Blum M, Kopetz ES, Ikoma N, Shatila M, Qiao W, Raju GS, Ross WA, Ge PS, Coronel E, Wang Y. Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. J Gastroenterol Hepatol 37(10):1983-1990, 2022. e-Pub 2022. PMID: 35730192.
25. Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O, Das P. Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. JCO Precis Oncol 6:e2200049, 2022. e-Pub 2022. PMID: 35952321.
26. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol 11(3):113-120, 2022. e-Pub 2022. PMID: 35837373.
27. Seervai RNH, Heberton M, Cho WC, Gill P, Murphy MB, Aung PP, Nagarajan P, Torres-Cabala CA, Patel AB, Ruiz-Bañobre J, Om A, Yamamoto T, Nikolaou V, Curry JL. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. J Cutan Pathol 49(5):472-481, 2022. e-Pub 2022. PMID: 34888886.
28. Bostock IC, Zhou N, Antonoff MB, Murphy MB, Lin S, Maru D, Mehran R, Rajaram R, Rice D, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Hofstetter W. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Dis Esophagus 35(4), 2022. e-Pub 2022. PMID: 34897440.
29. Serrano M, Araujo JM, Pacheco C, Macetas J, Blum MA, Carrato A, Ruiz E, Berrospi F, Luque C, Chavez I, Payet E, Taxa L, Montenegro P. Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer. Ecancermedicalscience 16:1387, 2022. e-Pub 2022. PMID: 35919233.
30. Davis CH, Ikoma N, Mansfield PF, Das P, Minsky BD, Blum MA, Ajani JA, Bass BL, Badgwell BD. Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. Surg Endosc 35(12):6577-6582, 2021. e-Pub 2021. PMID: 33170336.
31. Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, Wang L, Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut 70(11):2055-2065, 2021. e-Pub 2021. PMID: 33334899.
32. Allen CJ, Pointer DT, Blumenthaler AN, Mehta RJ, Hoffe SE, Minsky BD, Smith GL, Blum M, Mansfield PF, Ikoma N, Das P, Ajani J, Dineen SP, Fleming JB, Badgwell BD, Pimiento JM. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg 274(4):544-548, 2021. e-Pub 2021. PMID: 34132693.
33. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD, Ikoma N. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Ann Surg Oncol 28(11):6638-6648, 2021. e-Pub 2021. PMID: 33754224.
34. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery 170(4):1231-1239, 2021. e-Pub 2021. PMID: 34059344.
35. Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Mansfield P, Ajani JA, Badgwell BD. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg 25(6):1380-1387, 2021. e-Pub 2020. PMID: 32542556.
36. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg 273(4):751-757, 2021. e-Pub 2019. PMID: 31188215.
37. Erstad DJ, Blum M, Estrella JS, Das P, Minsky BD, Ajani JA, Mansfield PF, Ikoma N, Badgwell BD. Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. J Natl Compr Canc Netw 19(13):1-12, 2021. e-Pub 2021. PMID: 34678759.
38. Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol 123(4):911-922, 2021. e-Pub 2021. PMID: 33400838.
39. Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol 28(2):758-765, 2021. e-Pub 2021. PMID: 32696305.
40. Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med 27(1):141-151, 2021. e-Pub 2021. PMID: 33398161.
41. Abdelhakeem AA, Wang X, Waters RE, Patnana M, Estrella JS, Blum Murphy M, Trail AM, Lu Y, Devine CE, Ikoma N, Das P, Badgwell BD, Rogers JE, Ajani JA. Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers (Basel) 13(3):1-10, 2021. e-Pub 2021. PMID: 33498613.
42. Badgwell B, Ikoma N, Murphy MB, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Lano E, Song S, Mansfield P, Ajani J. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Ann Surg Oncol 28(1):258-264, 2021. e-Pub 2021. PMID: 32556731.
43. Abdelhakeem A, Patnana M, Wang X, Rogers JE, Murphy MB, Sagebiel T, Ikoma N, Badgwell BD, Trail A, Estrella JS, Lu Y, Devine C, Ajani JA. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. Oncology 99(10):659-664, 2021. e-Pub 2021. PMID: 34352788.
44. Blumenthaler AN, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. J Surg Oncol 122(7):1373-1382, 2020. e-Pub 2020. PMID: 32810292.
45. White MG, Kothari A, Ikoma N, Murphy MB, Song S, Ajani J, Mansfield P, Badgwell B. Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. Ann Surg Oncol 27(13):4963-4969, 2020. e-Pub 2020. PMID: 32648181.
46. Blumenthaler AN, Allen CJ, Ikoma N, Blum M, Das P, Minsky BD, Mansfield PF, Ajani JA, Badgwell BD. Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. Ann Surg Oncol 27(13):5047-5056, 2020. e-Pub 2020. PMID: 32737700.
47. Gironda DJ, Adams DL, He J, Xu T, Gao H, Qiao Y, Komaki R, Reuben JM, Liao Z, Blum-Murphy M, Hofstetter WL, Tang CM, Lin SH. Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy. J Transl Med 18(1):413, 2020. e-Pub 2020. PMID: 33148307.
48. Harada K, Patnana M, Wang X, Iwatsuki M, Murphy MAB, Zhao M, Das P, Minsky BD, Weston B, Lee JH, Bhutani MS, Estrella JS, Shanbhag N, Ikoma N, Badgwell BD, Ajani JA. Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. Surg Today 50(10):1223-1231, 2020. e-Pub 2020. PMID: 32409870.
49. Kim BJ, Chiang YJ, Das P, Minsky BD, Blum MA, Ajani JA, Estrella JS, Hofstetter WL, Tzeng CD, Badgwell BD, Mansfield PF, Ikoma N. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med 9(11), 2020. e-Pub 2020. PMID: 33138060.
50. Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol 122(3):422-432, 2020. e-Pub 2020. PMID: 32462681.
51. Deng W, Jethwa KR, Gonuguntla K, Liao Z, Yoon HH, Murphy MB, Haddock MG, Hallemeier CL, Lin SH. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Adv Radiat Oncol 5(5):951-958, 2020. e-Pub 2020. PMID: 33083658.
52. Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Murphy MAB, Maru DM, Weston B, Lee JH, Rogers JE, Trail A, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Das P, Hofstetter WL, Badgwell BD, Ajani JA. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer 23(5):904-912, 2020. e-Pub 2020. PMID: 32347396.
53. Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer 20(3):313-327, 2020. e-Pub 2020. PMID: 33024587.
54. Zafar SN, Blum M, Chiang YJ, Ajani JA, Estrella JS, Das P, Minsky BD, Hofstetter WL, Mansfield P, Badgwell BD, Ikoma N. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Ann Thorac Surg 110(2):398-405, 2020. e-Pub 2020. PMID: 32289300.
55. Blum Murphy M, Ikoma N, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Song S, Mansfield P, Ajani J, Badgwell B. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol 27(8):2806-2811, 2020. e-Pub 2020. PMID: 31974712.
56. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg 272(2):311-318, 2020. e-Pub 2020. PMID: 32675544.
57. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol 38(14):1569-1579, 2020. e-Pub 2020. PMID: 32160096.
58. Moningi S, Ajani JA, Badgwell BD, Murphy MB, Ikoma N, Mansfield PF, Ho JC, Suh Y, Crane C, Herman JM, Holliday EB, Koay E, Koong AC, Krishnan S, Minsky B, Smith G, Taniguchi C, Das P. IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol 5(3):369-376, 2020. e-Pub 2020. PMID: 32529130.
59. Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res 26(4):846-854, 2020. e-Pub 2020. PMID: 31676670.
60. Allen CJ, Vreeland TJ, Newhook TE, Das P, Minsky BD, Blum M, Ajani J, Ikoma N, Mansfield PF, Badgwell BD. Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Ann Surg Oncol 27(2):534-542, 2020. e-Pub 2020. PMID: 31552618.
61. Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Chin FW, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore) 99(9):e19295, 2020. e-Pub 2020. PMID: 32118743.
62. Allen CJ, Blumenthaler AN, Das P, Minsky BD, Blum M, Roy-Chowdhuri S, Ajani JA, Ikoma N, Mansfield PF, Badgwell BD. Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. World J Surg Oncol 18(1):39, 2020. e-Pub 2020. PMID: 32066454.
63. Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut 69(1):18-31, 2020. e-Pub 2020. PMID: 31171626.
64. Mizrak Kaya D, Nogueras González GM, Harada K, Blum Murphy MA, Lee JH, Bhutani MS, Weston B, Thomas I, Rogers JE, Das P, Badgwell BD, Ajani JA. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology 98(8):542-548, 2020. e-Pub 2020. PMID: 32434189.
65. Rogers JE, Xiao L, Trail A, Blum Murphy M, Palmer M, Ajani JA. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology 98(5):289-294, 2020. e-Pub 2020. PMID: 32097933.
66. Abdelhakeem A, Wang X, Rogers JE, Trail A, Zhao M, Blum-Murphy M, Estrella JS, Ajani JA. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology 98(12):884-888, 2020. e-Pub 2020. PMID: 32998149.
67. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech 12(12), 2019. e-Pub 2019. PMID: 31732509.
68. Nelson DB, Mitchell KG, Weston BR, Betancourt S, Maru D, Rice DC, Mehran RJ, Sepesi B, Antonoff MB, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Blum M, Hofstetter WL. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer?. Dis Esophagus 32(10):1-6, 2019. e-Pub 2019. PMID: 30888418.
69. Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M, Song S, Ajani J, Ikoma N, Mansfield PF, Roy-Chowdhuri S, Badgwell BD. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J Surg Oncol 120(8):1350-1357, 2019. e-Pub 2019. PMID: 31612494.
70. Sonoda K, Samdani RT, Ikoma N, Kaya DM, Blum-Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS. Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. J Surg Oncol 120(7):1137-1141, 2019. e-Pub 2019. PMID: 31498442.
71. Ikoma N, Agnes A, Chen HC, Wang X, Blum MM, Das P, Minsky B, Estrella JS, Mansfield P, Ajani JA, Badgwell BD. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg. e-Pub 2019. PMID: 31754987.
72. Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol 26(11):3602-3610, 2019. e-Pub 2019. PMID: 31350645.
73. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. e-Pub 2019. PMID: 31529018.
74. Mitchell KG, Ikoma N, Nelson DB, Maru DM, Erasmus JJ, Weston BR, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Swisher SG, Sepesi B, Walsh GL, Correa AM, Das P, Blum MA, Badgwell BD, Hofstetter WL. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Ann Thorac Surg 108(3):845-851, 2019. e-Pub 2019. PMID: 31102632.
75. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget 10(45):4703-4718, 2019. e-Pub 2019. PMID: 31384397.
76. Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, Ajani JA, Minsky BD, Mansfield P, Badgwell BD. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol 26(5):1394-1400, 2019. e-Pub 2019. PMID: 30680477.
77. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. e-Pub 2019. PMID: 30720506.
78. Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology 96(5):252-258, 2019. e-Pub 2019. PMID: 30893708.
79. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
80. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol 11:1758835919864850, 2019. e-Pub 2019. PMID: 31384313.
81. Ikoma N, Estrella JS, Blum M, Das P, Chen HC, Wang X, Fournier K, Mansfield P, Ajani J, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg 22(8):1325-1333, 2018. e-Pub 2018. PMID: 29679346.
82. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg 268(2):289-295, 2018. e-Pub 2018. PMID: 28628563.
83. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol 128(1):154-160, 2018. e-Pub 2018. PMID: 29248170.
84. Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, Devine CE, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer 98:23-29, 2018. e-Pub 2018. PMID: 29859338.
85. Thiels CA, Ikoma N, Fournier K, Das P, Blum M, Estrella JS, Minsky BD, Ajani J, Mansfield P, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. e-Pub 2018. PMID: 29878364.
86. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology:1-10. e-Pub 2018. PMID: 29843157.
87. Blum Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, Ajani J. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol 41(4):321-325, 2018. e-Pub 2018. PMID: 26908161.
88. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94(6):345-353. e-Pub 2018. PMID: 29705797.
89. Bozkurt M, Antonoff M, Jaramillo S, Sagebiel T, Murphy MB. Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature. J Gastrointest Cancer. e-Pub 2018. PMID: 29577180.
90. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol 13(1):99-106, 2018. e-Pub 2018. PMID: 29218623.
91. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer 118(3):331-337, 2018. e-Pub 2018. PMID: 29235564.
92. Badgwell B, Blum M, Das P, Estrella J, Wang X, Fournier K, Royal R, Mansfield P, Ajani J. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc 32(1):512, 2018. e-Pub 2018. PMID: 28643069.
93. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 21(1):74-83, 2018. e-Pub 2018. PMID: 28643144.
94. Samudrala P, Cruz-Carreras MT, Murphy MB, Rice T. Sub-acute herpes simplex virus myelitis in a patient with esophageal cancer on chemo-radiation with 5-fluorouracil: a case report. Acute Med 17(3):156-159, 2018. e-Pub 2018. PMID: 30129950.
95. Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol 8(6):1009-1017, 2017. e-Pub 2017. PMID: 29299361.
96. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer 123(21):4106-4113, 2017. e-Pub 2017. PMID: 28885712.
97. Ikoma N, Das P, Blum M, Estrella JS, Devine CE, Wang X, Fournier K, Mansfield P, Minsky BD, Ajani J, Badgwell BD. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. Int J Radiat Oncol Biol Phys 99(3):660-666, 2017. e-Pub 2017. PMID: 29280460.
98. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 99(3):667-676, 2017. e-Pub 2017. PMID: 29280461.
99. Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget 8(46):81430-81440, 2017. e-Pub 2017. PMID: 29113402.
100. Atay SM, Blum M, Sepesi B. Adjuvant chemotherapy following trimodality therapy for esophageal carcinoma-Is the evidence sufficient?. J Thorac Dis 9(10):3626-3629, 2017. e-Pub 2017. PMID: 29268359.
101. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget 8(45):79356-79365, 2017. e-Pub 2017. PMID: 29108314.
102. Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, Ajani J, Badgwell BD. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol 24(9):2679-2687, 2017. e-Pub 2017. PMID: 28332034.
103. Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, Fournier K, Royal R, Mansfield P, Ajani J. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. e-Pub 2017. PMID: 28799004.
104. Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Harada K, Rogers JE, Mares J, Amlashi FG, Minsky BD, Das P, Hofstetter WL, Matamoros A, Sagebiel TL, Blum-Murphy MA, Lee JH, Weston B, Bhutani MS, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol 24(8):2291-2301, 2017. e-Pub 2017. PMID: 27770339.
105. Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 124(2):318-324, 2017. e-Pub 2017. PMID: 28687396.
106. Bozkurt M, Amlashi FG, Blum Murphy M. The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. Minerva Chir 72(4):317-333, 2017. e-Pub 2017. PMID: 28415835.
107. Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. J Gastrointest Surg. e-Pub 2017. PMID: 28819789.
108. Shi A, Liao Z, Allen PK, Ho L, Murphy MB, Maru DM, Swisher SG, Hofstetter WL, Mehran RJ, Cox JD, Komaki R, Lin SH. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. Adv Radiat Oncol 2(3):316-324, 2017. e-Pub 2017. PMID: 29114598.
109. Xi M, Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. J Thorac Oncol 12(6):1001-1010, 2017. e-Pub 2017. PMID: 28351804.
110. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget. e-Pub 2017. PMID: 28611281.
111. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani J, Badgwell BD. Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. Ann Surg Oncol 24(4):960-965, 2017. e-Pub 2017. PMID: 27778127.
112. Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol 35(4):475-477, 2017. e-Pub 2017. PMID: 28129519.
113. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol 12(2):375-382, 2017. e-Pub 2017. PMID: 27794500.
114. Blum Murphy M, Ajani J. Immune Checkpoint Inhibitors in Advanced Gastroesophageal Cancers. 2017 ASCO, 2017. e-Pub 2017.
115. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology 93(4):243-248, 2017. e-Pub 2017. PMID: 28683449.
116. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol 23(13):4332-4337, 2016. e-Pub 2016. PMID: 27384751.
117. Badgwell B, Blum M, Estrella J, Ajani J. Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. Lancet Oncol 17(12):1628-1629, 2016. e-Pub 2016. PMID: 27776842.
118. Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Survival rates in T1 and T2 gastric cancer: A Western report. J Surg Oncol 114(5):602-606, 2016. e-Pub 2016. PMID: 27439746.
119. Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, Blum MA, Estrella J, Matamoros A, Sagebiel T, Devine CE, Badgwell BD, Lin QD, Das P, Ajani JA. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. J Gastrointest Oncol 7(4):499-505, 2016. e-Pub 2016. PMID: 27563438.
120. Blum Murphy M. Adjunctive Therapy of Gastric Cancer: Moving the Field Forward. Oncology (Williston Park) 30(7), 2016. e-Pub 2016. PMID: 27422111.
121. Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P, Mansfield P, Ajani J. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol 23(6):1948-55, 2016. e-Pub 2016. PMID: 26868957.
122. Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. e-Pub 2016. PMID: 27120436.
123. Blum Murphy MA, Elimova E, Ajani JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol 10(3):1-10, 2016. e-Pub 2016. PMID: 26560689.
124. Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw 14(2):173-9, 2016. e-Pub 2016. PMID: 26850487.
125. Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology 90(5):239-47, 2016. e-Pub 2016. PMID: 27046280.
126. Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 51(17):2545-52, 2015. e-Pub 2015. PMID: 26321501.
127. Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?. Ann Surg Oncol. e-Pub 2015. PMID: 26564243.
128. Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. e-Pub 2015. PMID: 26482869.
129. Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. e-Pub 2015. PMID: 26393501.
130. Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients - Does It Make a Difference?. Oncology. e-Pub 2015. PMID: 26159599.
131. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, Ajani J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg 221(1):83-90, 2015. e-Pub 2015. PMID: 26002780.
132. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. e-Pub 2015. PMID: 26059652.
133. Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol 111(7):875-81, 2015. e-Pub 2015. PMID: 25872485.
134. Neishaboori N, Wadhwa R, Nogueras-González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. e-Pub 2015. PMID: 25765719.
135. Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology 88(6):332-6, 2015. e-Pub 2015. PMID: 25765098.
136. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 32(30):3400-5, 2014. e-Pub 2014. PMID: 25225435.
137. Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, Ajani JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw 12(8):1139-44, 2014. e-Pub 2014. PMID: 25099446.
138. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget 5(7):1837-45, 2014. e-Pub 2014. PMID: 24742823.
139. Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology 86(5-6):336-9, 2014. e-Pub 2014. PMID: 24925190.
140. Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 31(34):4306-10, 2013. e-Pub 2013. PMID: 24145339.
141. Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, Ajani JA. Chemoradiation for esophageal cancer. Thorac Surg Clin 23(4):551-8, 2013. e-Pub 2013. PMID: 24199704.
142. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors Associated with Local-Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer. Ann Surg Oncol. e-Pub 2013. PMID: 24197760.
143. Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh JW, Swisher SG, Hofstetter WL, Cancer Group UOTMAE. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg 258(3):500-7, 2013. e-Pub 2013. PMID: 24022442.
144. Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, Ajani JA. Ramucirumab: a novel antiangiogenic agent. Future Oncol 9(6):789-95, 2013. e-Pub 2013. PMID: 23718298.
145. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am 42(2):359-69, 2013. e-Pub 2013. PMID: 23639645.
146. Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant Therapy in Gastric Cancer: What Is The Optimal Approach?. Curr Oncol Rep. e-Pub 2013. PMID: 23355076.
147. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. J Surg Oncol. e-Pub 2013. PMID: 23303654.
148. Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology 85(2):95-9, 2013. e-Pub 2013. PMID: 23860252.
149. Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology 85(4):204-7, 2013. e-Pub 2013. PMID: 24051869.
150. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer. Eur J Cancer 48(18):3396-404, 2012. e-Pub 2012. PMID: 22853875.
151. Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A, Blum MA, Ajani JA, Onodera H. Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. Clin J Gastroenterol 5(5):355-60, 2012. e-Pub 2012. PMID: 26181075.
152. Blum MA, Suzuki A, Taketa T, Ajani J. Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. Future Medicine 9(4):463-471, 2012. e-Pub 2012.
153. Blum MA, Suzuki A, Taketa T, Ajani JA. Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. Clinical Practice Vol 9(No 4):463-471, 2012. e-Pub 2012.
154. Blum MA, Ajani JA. Therapy: Localized gastric cancer-a CLASSIC shift in the paradigm?. Nat Rev Gastroenterol Hepatol 9(4):194-5, 2012. e-Pub 2012. PMID: 22392288.
155. Ajani JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric Cancer: Apples Will Always Be Apples. J Clin Oncol 30(9):1017-8, 2012. e-Pub 2012. PMID: 22331947.
156. Blum MA, Hayashi Y, Ajani JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie 35(4):204-9, 2012. e-Pub 2012. PMID: 22488092.
157. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. Oncology 83(5):300-304, 2012. e-Pub 2012. PMID: 22964903.
158. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for Prognostication of Outcome in Patients with Esophageal and Gastroesophageal Carcinoma Undergoing Definitive Chemoradiotherapy. Oncology 82(2):108-113, 2012. e-Pub 2012. PMID: 22328056.
159. Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized Gastric Cancer Treated with Chemoradation without Surgery: UTMD Anderson Cancer Center Experience. Oncology 82(6):347-351, 2012. e-Pub 2012. PMID: 22677933.
160. Blum MA, Suzuki A, Taketa T, Ajani J. The role of S-1 in the treatment of Gastric Cancer. Gastrointestinal Cancer: Targets and Therapy 1(1):59-67, 2011. e-Pub 2011.
161. Blum M, Suzuki A, Ajani JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol 7(6):715-26, 2011. e-Pub 2011. PMID: 21675835.

Invited Articles

1. Pabon Cindy M, Li Jenny, Ajani Jaffer A., Blum Murphy M. Recent Advances in Perioperative Immunotherapy in Gastroesophageal and Gastric Cancers, 2024. e-Pub 2024.

Review Articles

1. Li, JJ, Rogers, JE, Waters, R, Gan, Q, Blum Murphy, M, Ajani, JA. Evolution of Therapeutics for Locally Advanced Upper Gastrointestinal Adenocarcinoma. Cancers 17(8), 2025. e-Pub 2025.
2. Pabon CM, Spieler B, Li JJ, Ajani J, Hosein PJ, Blum Murphy M. Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?. Oncologist 30(1), 2025. e-Pub 2025. PMID: 39846982.
3. Li JJ, Rogers JE, Yamashita K, Waters RE, Blum Murphy M, Ajani JA. Therapeutic Advances in the Treatment of Gastroesophageal Cancers. Biomolecules 13(5), 2023. e-Pub 2023. PMID: 37238666.
4. Abdelhakeem, AA, Blum Murphy, M. Adjuvant Therapies for Esophageal Cancer. Thoracic surgery clinics 32(4):457-465, 2022. e-Pub 2022. PMID: 36266033.
5. Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S, Roblin X, Sibilia J, Blum M, Danese S, Bonovas S, Peyrin-Biroulet L. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun 80:10-27, 2017. e-Pub 2017. PMID: 28381345.
6. Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 20(38):13637-13647, 2014. e-Pub 2014. PMID: 25320502.
7. Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, Ajani JA. Anti-angiogenic agent ramucirumab: meaningful or marginal?. Expert Rev Anticancer Ther 14(4):367-79, 2014. e-Pub 2014. PMID: 24605771.

Professional Educational Materials

1. Elimova E, Wadhwa R, Charalampakis N, Phan AT, Das P, Blum M. Gastric and Esophageal Cancer The MD Anderson Manual of Medical Oncology. McGraw-Hill Publish, 2015.
2. Karp D, Falchook GS. Handbook of Targeted Cancer Therapy. Wolters Kluwer, 2014.

Editorials

1. Blum Murphy M, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense?. J Natl Compr Canc Netw 10(12):1590-92, 2012. PMID: 23221793.
2. Blum MA, Ajani JA. Chemoradiation: Gastro-oesophageal cancer-is CROSSing over so hard to do?. Nat Rev Clin Oncol 9(9):493-4, 2012. PMID: 22825372.
3. Blum Murphy MA, Taketa T, Sudo K, Lee JH, Ajani JA. Surveillance for esophageal cancer: does it make sense?. J Natl Compr Canc Netw 10:1590-92, 2012.
4. Blum MA, Ajani JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie 34(10):499-500, 2011. PMID: 21985847.

Abstracts

1. Ludford, Kaysia, Ho, Jin W, Thomas, Jane V, Raghav, Kanwal PS, Murphy, Blum M, Fleming, Nicole D, Lee, Michael S, Smaglo, Brandon G, You, Nancy Y, Tillman, Matthew M, Kamiya-Matsuoka, Carlos, Thirumurthi, Selvi, Messick, Craig, Johnson, Benny, Vilar, Eduardo, Dasari, Arvind, Shin, Sarah, Hernandez, Alexei, Yuan, Xuan, Yang, Hongqui, Foo, Chin W, Qiao, Wei, Maru, Dipen, Kopetz, Scott, Overman, Michael J. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Journal of Clinical Oncology 41(12):2181-2190(10), 2023. e-Pub 2023.
2. Overman MJ, Melhem R, Blum-Murphy MA, Ramos C, Petrosyan L, Li J, Perer JK, Zou H, Wang M, Wright HM. A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas. Journal of Clinical Oncology 41(4_suppl):TPS765-TPS765, 2023. e-Pub 2023.
3. Kato K, Ajani JA, Doki Y, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu C, Adenis A, Hajbi FE, Bartolomeo MD, Melro Braghiroli MIF, Holtved E, Blum Murphy MA, Patel A, Hu N, Matsumura Y, Chau I, Kitagawa Y. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. Journal of Clinical Oncology 41(4_suppl):290-290, 2023. e-Pub 2023.
4. Blum Murphy MA, Ajani JA, Van Tine BA, Clarke JM, Butler MO, Lawrence DP, Johnson ML, Cervantes A, Moreno V, Hong DS, Brophy FE, Navenot J, Lin Q, Saro J, Norry E. Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer. Journal of Clinical Oncology 41(4_suppl):349-349, 2023. e-Pub 2023.
5. Blum Murphy MA, Nogueras Gonzalez GM, Sewastjanow-Silva M, Wang X, Hofstetter WL, Swisher S, Mehran RJ, Sepesi B, Bhutani MS, Weston B, Coronel E, Waters RE, Rogers JE, Smith J, Lyons L, Reilly N, Yao JC, Ajani JA. Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma. Journal of Clinical Oncology 41(4_suppl):400-400, 2023. e-Pub 2023.
6. Wang R, Song S, Harada K, Amlashi FG, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Murphy MB, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut 69(1):18-31, 2020. e-Pub 2020.
7. Sonoda K, Samdani RT, Ikoma N, Kaya DM, Blum-Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS. Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. Journal of surgical oncology 120(7):1137-1141, 2019. e-Pub 2019.
8. Allen CJ, Newhook TE, Vreeland TJ, Das P, Minsky BD, Blum M, Song S, Ajani J, Ikoma N, Mansfield PF, Roy-Chowdhuri S, Badgwell BD. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. Journal of surgical oncology 120(8):1350-1357, 2019. e-Pub 2019.
9. Nelson DB, Mitchell KG, Weston BR, Betancourt S, Maru D, Rice DC, Mehran RJ, Sepesi B, Antonoff MB, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Blum M, Hofstetter WL. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer?. Diseases of the Esophagus 32(10), 2019. e-Pub 2019.
10. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW. Results of a Phase 1/2 Trial of Chemoradiotherapy with Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncology 5(11):1597-1604, 2019. e-Pub 2019.
11. Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Annals of surgical oncology 26(11):3602-3610, 2019. e-Pub 2019.
12. Mitchell KG, Ikoma N, Nelson DB, Maru DM, Erasmus JJ, Weston BR, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Swisher SG, Sepesi B, Walsh GL, Correa AM, Das P, Blum MA, Badgwell BD, Hofstetter WL. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Annals of Thoracic Surgery 108(3):845-851, 2019. e-Pub 2019.
13. Bozkurt M, Antonoff M, Jaramillo S, Sagebiel T, Murphy MB. Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature. Journal of Gastrointestinal Cancer, 2019. e-Pub 2019.
14. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Therapeutic Advances in Medical Oncology 11, 2019. e-Pub 2019.
15. Newhook TE, Agnes A, Murphy MB, Estrella JS, Das P, Ho L, Ajani JA, Minsky B, Mansfield PF, Badgwell BD. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Annals of surgical oncology 26(5):1394-1400, 2019. e-Pub 2019.
16. Rogers JE, Xiao L, Amlashi FG, Elimova E, Murphy MB, Sanders E, Shanbhag N, Thomas I, Ajani JA. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology (Switzerland) 96(5):252-258, 2019. e-Pub 2019.
17. Ikoma N, Agnes A, Chen HC, Wang X, Blum MM, Das P, Minsky B, Estrella JS, Mansfield P, Ajani JA, Badgwell BD. Linitis Plastica: a Distinct Type of Gastric Cancer. Journal of Gastrointestinal Surgery, 2019. e-Pub 2019.
18. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget 10(45):4703-4718, 2019. e-Pub 2019.
19. Allen CJ, Vreeland TJ, Newhook TE, Das P, Minsky BD, Blum M, Ajani J, Ikoma N, Mansfield PF, Badgwell BD. Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Annals of surgical oncology, 2019. e-Pub 2019.
20. Thiels CA, Ikoma N, Fournier KF, Das P, Murphy MB, Estrella JS, Minsky B, Ajani JA, Mansfield PF, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. Journal of Surgical Oncology 118(1):61-67, 2018. e-Pub 2018.
21. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiotherapy and Oncology 128(1):154-160, 2018. e-Pub 2018.
22. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani M, Lee JH, Weston B, Kaya DM, Vassilakopoulou M, Harada K, Murphy MB, Rice DC, Hofstetter WL, Davila M, Nguyen Q, Ajani JA. Barrett's esophagus after bimodality therapy in patients with esophageal adenocarcinoma. Oncology (Switzerland) 95(2):81-90, 2018. e-Pub 2018.
23. Lopez A, Chen H, Harada K, Bhutani MS, Weston B, Lee JH, Maru DM, Foo WC, Rogers JE, Thomas I, Amlashi FG, Blum Murphy MA, Rice DC, Hofstetter WL, Nguyen Q, Ajani JA. Maintenance therapy with trastuzumab +/- fluoropyrimidine in non-progressive HER-2 positive advanced gastroesophageal cancer patients after first-line chemotherapy. Jounal of Clinical Oncology, 2018. e-Pub 2018.
24. Yap TA, Burris HA, Kummar S, Falchook GS, Pachynski RK, LoRusso P, Tykodi SS, Gibney GT, Gainor JF, Rahma OE, Seiwert TY, Meric-Bernstam F, Blum Murphy MA, Litton JK, Diament Hooper EM, Hirsch HA, Harvey C, Clancy M, McClure T, Callahan MK. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
25. Kelly RJ, Lee J, Bang Y, Almhanna K, Blum Murphy MA, Catenacci DV, Chung HC, Wainberg ZA, Gibson M, Lee KW, Bendell JC, Denlinger CS, Brohawn PZ, He P, McDevitt J, Englert J, Ku GY. Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
26. Meric-Bernstam F, Beeram M, Mayordomo JI, Hanna DL, Ajani JA, Blum Murphy MA, Murthy RK, Piha-Paul SA, Bauer TM, Bendell JC, El-Khoueiry AB, Lenz H, Press MF, Royer N, Hausman DF, Hamilton EP. Single agent activity of ZW25, a HER2‑targeted bispecific antibody, in heavily pretreated HER2‑expressing cancers. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
27. Lopez A, Chen H, Harada K, Bhutani MS, Weston B, Lee JH, Maru DM, Foo WC, Rogers JE, Thomas I, Amlashi FG, Blum Murphy MA, Rice DC, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Journal of Clinical Oncology, 2018. e-Pub 2018.
28. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani M, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Kaya DM, Lopez A, Murphy MB, Roth JA, Swisher SG, Skinner H, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh GL, Ajani JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Targeted oncology 13(1):99-106, 2018. e-Pub 2018.
29. Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani M, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Kaya DM, Murphy MB, Roth JA, Swisher SG, Skinner H, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh GL, Ajani JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: Secondary analysis of a randomised trial. British journal of cancer 118(3):331-337, 2018. e-Pub 2018.
30. Samudrala P, Cruz-Carreras MT, Murphy MB, Rice T. Sub-acute herpes simplex virus myelitis in a patient with esophageal cancer on chemo-radiation with 5-fluorouracil: A case report. Acute Medicine 17(4):156-159, 2018. e-Pub 2018.
31. Kaya DM, Nogueras-Gonzalez GM, Estrella J, Harada K, Amlashi FG, Lin Q, Blum Murphy MA, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel TL, Devine CE, Patnana M, Minsky BD, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma (GAC) patients treated without surgery. 2018 Gastrointestinal Cancers Symposium, 2018. e-Pub 2018.
32. Harada K, Wu CC, Wang X, Kaya DM, Amlashi FG, Lin Q, Blum Murphy MA, Maru DM, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Nguyen Q, Ajani JA. Metabolic activity to predict clinical response and prognosis in esophageal adenocarcinoma patients treated with bimodality. 2018 Gastrointestinal Cancers Symposium, 2018. e-Pub 2018.
33. Badgwell BD, Murphy MB, Das P, Estrella JS, Wang X, Fournier KF, Royal RE, Mansfield PF, Ajani JA. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surgical endoscopy 32(1):1, 2018. e-Pub 2018.
34. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 21(1):74-83, 2018. e-Pub 2018.
35. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology (Switzerland) 94(6):345-353, 2018. e-Pub 2018.
36. Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, Ajani J. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients with Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. American Journal of Clinical Oncology: Cancer Clinical Trials 41(4):321-325, 2018. e-Pub 2018.
37. Kaya DM, Nogueras-Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani M, Lee JH, Weston B, Minsky B, Estrella JS, Murphy MB, Jr AM, Devine CE, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma treated without surgery. European Journal of Cancer 98:23-29, 2018. e-Pub 2018.
38. Ikoma N, Estrella JS, Murphy MB, Das P, Chen HC, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. Journal of Gastrointestinal Surgery 22(8):1325-1333, 2018. e-Pub 2018.
39. Kaya DM, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella J, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel TL, Skinner HD, Wu CC, Hofstetter WL, Badgwell BD, Ajani JA. Long-term survival in 101 metastatic gastroesophageal cancer (mGEAC) patients eventually treated with consolidative local therapy. 2017 Gastrointestinal Cancers Symposium, 2017. e-Pub 2017.
40. Kaya DM, Nogueras-Gonzalez GM, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella J, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Wu CC, Matamoros A, Sagebiel TL, Mansfield PF, Badgwell BD, Ajani JA. Risk of peritoneal carcinomatosis in localized gastric adenocarcinoma patients who undergo preoperative therapy and attempted surgery. 2017 Gastrointestinal Cancers Symposium, 2017. e-Pub 2017.
41. Ikoma N, Chen H, Wang X, Blum Murphy MA, Estrella J, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Recurrence patterns of gastric cancer in the era of preoperative therapy. 2017 Gastrointestinal Cancers Symposium, 2017. e-Pub 2017.
42. Blum Murphy MA. Chair - General Session 2: Advances in Systemic Therapy for Esophageal and Gastric Cancer (ARS). 2017 Gastrointestinal Cancers Symposium, 2017. e-Pub 2017.
43. Ikoma N, Estrella J, Blum Murphy MA, Chen H, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Lymph node metastasis in gastric cancer: Location of positive station to predict survival after preoperative therapy. 2017 Gastrointestinal Cancers Symposium, 2017. e-Pub 2017.
44. Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Shiozaki H, Minsky BD, Das P, Hofstetter WL, Swisher S, Skinner HD, Maru DM, Matamoros A, Blum M, Lee JH, Weston B, Bhutani MS, Mansfield PF, Badgwell BD, Ajani JA. Outcomes in older patients with localized gastric adenocarcinoma treated preoperatively. 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
45. Al-Shamsi HO, Rogers J, Mares JE, Blum MA, Dahbour I, Fahmawi Y, Lin Q, Ajani JA, Cancer Center TUOTMA, Houston, TX. Continuation of trastuzumab beyond disease progression in patient with metastatic gastric cancer: A retrospective analysis of 25 cases- The MD Anderson experience. 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
46. Elimova E, Kim S, Wang X, Shimodaira Y, Sohn BH, Skinner HD, Lee JH, Weston B, Bhutani MS, Minsky BD, Rice DC, Hwang JE, Swisher S, Hofstetter WL, Blum MA, Maru DM, Ajani JA, Lee J, Cancer Center TUOTMA, Houston, TX, Medical School JNU, Hospital, Jeonju, Korea N, Systems Biology DO, Houston, TX, Medical Center TUOC, Chicago, IL. Correlation of pretreatment p63-positive subtype of gastroesophageal adenocarcinoma (GEAC) with pathologic complete response (pathCR) in patients receiving preoperative chemoradiation. 2016 Gastrointestinal Cancers Symposium, 2016. e-Pub 2016.
47. Ikoma N, Elimova E, Blum MA, Ajani JA, Chiang Y, Fournier KF, Mansfield PF, Badgwell BD, Cancer Center TUOTMA, Houston, TX, Cancer Center TUOTMA, City M, TX. Staging Laparoscopy with Cytology Analysis in Gastric Cancer. 2016 Gastrointestinal Cancers Symposium, 2016. e-Pub 2016.
48. Charalampakis N, Xiao L, Elimova E, Shimodaira Y, Shiozaki H, Das P, Matamoros A, Sagebiel TL, Blum MA, Lee JH, Bhutani MS, Weston B, Mansfield PF, Minsky BD, Badgwell BD, Ajani JA. Course and predictors of postoperative outcomes in older patients with localized localized gastric adenocarcinoma treated preoperatively. 2016 Gastrointestinal Cancers Symposium, 2016. e-Pub 2016.
49. Badgwell BD, Blum MA, Das P, Elimova E, Mansfield PF, Ajani JA. A phase II study of laparoscopic hyperthermic intraperitoneal chemoperfusion (HIPEC) for gastric carcinomatosis or positive cytology. 2016 Gastrointestinal Cancers Symposium, 2016. e-Pub 2016.
50. Ikoma N, Elimova E, Blum MA, Ajani JA, Chiang Y, Fournier KF, Mansfield PF, Badgwell BD, Cancer Center TUOTMA, Houston, TX, Cancer Center TUOTMA. Risk Factors for Survival in Early T Stage Gastric Cancer. 2016 Gastrointestinal Cancers Symposium, 2016. e-Pub 2016.
51. Shimodaira Y, Slack R, Chen H, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Harada K, Amlashi FG, Mizrak D, Blum MA, Roth JA, Swisher S, Skinner HD, Hofstetter WL, Komaki R, Walsh GL, Ajani JA, Cancer Center TUOTMA, Houston, TX, Medical Oncology TUOTMACCDOG, Houston, TX, Radiation Oncology DO, Cancer Center TUOTMA, Houston, TX. Influence of induction chemotherapy (IC) in trimodality-eligible esophageal cancer patients: Secondary analysis of a randomized trial. 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
52. Ikoma N, Elimova E, Blum MA, Ajani JA, Chiang Y, Fournier KF, Mansfield PF, Badgwell BD, Cancer Center TUOTMA, Houston, TX. Preoperative accuracy of gastric cancer staging in patient selection for neoadjuvant therapy. 2016 Gastrointestinal Cancers Symposium, 2016. e-Pub 2016.
53. Charalampakis N, Nogueras-Gonzalez GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Garris J, Matamoros A, Sagebiel TL, Das P, Estrella J, Badgwell BD, Ajani JA, Cancer Center TUOTMA, Houston, TX, Clinical Programs DOP, Cancer Center TUOTMA, Houston, TX. Signet ring cell (SRC) histology of localized gastric adenocarcinoma (LGAC) to predict response to preoperative chemoradiation. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
54. Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Planjery V, Charalampakis N, Skinner HD, Lee JH, Weston B, Bhutani MS, Komaki R, Rice DC, Swisher S, Blum MA, Maru DM, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX, Biostatistics DO, Cancer Center TUOTMA, Houston, TX. Actionable locoregional failures (LRFs) after therapy of localized esophageal carcinoma (LEC): Surveillance strategies and their benefits. 2015 Gastrointestinal Cancers Symposium, 2015. e-Pub 2015.
55. Shimodaira Y, Elimova E, Shiozaki H, Wadhwa R, Charalampakis N, Planjery V, Blum MA, Nguyen Q, Skinner HD, Slack R, Maru DM, Hofstetter WL, Weston B, Bhutani MS, Lee JH, Ajani JA, Cancer Center TUOTMA, Houston, TX. Accuracy of EUS-FNA for distant regional lymph nodes in the initial staging of esophageal cancer (EC). 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
56. Charalampakis N, Nogueras-Gonzalez GM, Wang X, Elimova E, Shiozaki H, Wadhwa R, Planjery V, Garris J, Rogers JE, Hiremath A, Blum MA, Lee JH, Bhutani MS, Weston B, Estrella J, Matamoros A, Das P, Badgwell BD, Ajani JA, Cancer Center TUOTMA, Houston, TX, Clinical Programs DOP, Cancer Center TUOTMA, Houston, TX. Association of histologic grade and subtypes of gastric cancer (GC) with chemoradiation response. 2015 Gastrointestinal Cancers Symposium, 2015. e-Pub 2015.
57. Blum MA, Xiao L, Correa AM, Wadhwa R, Elimova E, Skinner HD, Komaki R, Lee JH, Bhutani MS, Weston B, Liao ZX, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Analysis of patients with esophageal cancer following trimodality therapy: Pathological complete remission (PathCR) versus non-PathCR. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
58. Shiozaki H, Elimova E, Slack R, Chen H, Staerkel GA, Sneige N, Planjery V, Charalampakis N, Wadhwa R, Sudo K, Matamoros A, Lee JH, Weston B, Bhutani MS, Blum MA, Estrella J, Das P, Mansfield PF, Badgwell BD, Ajani JA, Cancer Center TUOTMA, Houston, TX, Hospital HM, Houston, TX. Prognosis of gastric cancer (GC) patients with positive peritoneal cytology. 2015 Gastrointestinal Cancers Symposium, 2015. e-Pub 2015.
59. Sudo K, Wang X, Wadhwa R, Shiozaki H, Hofstetter WL, Rice DC, Lee JH, Bhutani MS, Weston B, Skinner HD, Komaki R, Maru DM, Blum MA, Ajani JA, eancer Center TUOTMA, Houston, TX. Clinical parameters’ model for predicting distant metastasis (DM) following definitive therapy in patients with localized esophageal and esophagogastric junction (E-EGJ). 2014 Gastrointestinal Cancers Symposium, 2014. e-Pub 2014.
60. Elimova E, Wadhwa R, Sudo K, Shiozaki H, Slack R, Chen H, Badgwell BD, Matamoros A, Lee JH, Weston B, Bhutani MS, Blum MA, Estrella J, Das P, Ajani JA, Center MD, Houston, TX, Cancer Center TUOTMA, Houston, TX. A phase II study of preoperative chemotherapy and chemoradiation for localized gastric and gastroesophageal junction adenocarcinoma (LGCA). 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
61. Shiozaki H, Sudo K, Wadhwa R, Hofstetter WL, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Maru DM, Blum MA, Ajani JA, Cancer Center TUOTMA, Houston, TX. Distribution and timing of distant metastasis (DM) after definitive therapy for patients with esophageal and esophagastric junction (E-EGJ) cancer. 2014 Gastrointestinal Cancers Symposium, 2014. e-Pub 2014.
62. Wadhwa R, Wang X, Izzo J, Skinner HD, Lee JH, Bhutani MS, Weston B, Ross WA, Hofstetter WL, Maru DM, Rice DC, Sudo K, Shiozaki H, Blum MA, Chen Q, Jin J, Song S, Baladandayuthapani V, Ajani JA, Cancer Center TUOTMA, Houston, TX. Correlation of pretreatment nuclear GLI-1 labeling indices (LIs) with initial SUV (iSUV) in esophageal cancer (EC) patients undergoing trimodality therapy (TMT): A potential pathway to esophageal preservation. 2014 Gatrointestinal Cancers Symposium, 2014. e-Pub 2014.
63. Shiozaki H, Sudo K, Wadhwa R, Elimova E, Slack R, Chen H, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX, Center MD, Houston, TX. Effect of the distribution of lymph node metastases on outcomes for trimodality-eligible patients with esophageal and esophagogastric junction adenocarcinoma (EAC). 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
64. Wadhwa R, Elimova E, Sudo K, Shiozaki H, Slack R, Chen H, Badgwell BD, Matamoros A, Lee JH, Weston B, Bhutani MS, Blum MA, Estrella J, Das P, Ajani JA, Cancer Center TUOTMA, Houston, TX, Center MD, Houston, TX. Outcomes of asymptomatic metastatic gastric cancer (MGC) patients when the initiation of systemic therapy is delayed. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
65. Taketa T, Xiao L, Suzuki A, Blum MA, Sudo K, Lee JH, Weston B, Bhutani MS, Lin SH, Wadhwa R, Swisher S, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX. 16 co-variate propensity score matching between trimodality (TMT)-eligible esophagogastric cancer (EC) patients who had surgery and those who declined surgery after preoperative chemoradiation. 2013 Gastrointestinal Cancer Symposium, 2013. e-Pub 2013.
66. Suzuki A, Xiao L, Taketa T, Sudo K, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Swisher S, Ajani JA, International Hospital SL, Tokyo, Japan, Cancer Center TUOTMA, Houston, TX. Various clinical outcomes in patients with esophageal or gastroesophageal junction (E-GEJ) adenocarcinoma undergoing trimodality thrapy: Prognostic implications. 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
67. Wadhwa R, Taketa T, Correa AM, Sudo K, Blum MA, Campagna M, Komaki R, Lee JH, Bhutani MS, Weston B, Liao ZX, Rice DC, Swisher S, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX. Incidence of brain metastases following trimodality therapy (TMT) in patients with esophageal and gastroesophageal (E-EGCJ). 2013 Gastrointestinal Cancers Symposium, 2013. e-Pub 2013.
68. Taketa T, Correa AM, Sudo K, Blum MA, Wadhwa R, Skinner HD, Komaki R, Lee JH, Bhutani MS, Weston B, Liao ZX, Rice DC, Swisher S, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX. Customizing surveillance of patients with esophageal or esophagogastric junction adenocarcinoma (E-EGA) after trimodality therapy (TMT). 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
69. Sudo K, Xiao L, Wadhwa R, Taketa T, Blum MA, Skinner HD, Lee JH, Bhutani MS, Weston B, Komaki R, Rice DC, Swisher S, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX. Pattern of local-regional relapse and survival after bimodality therapy for esophageal cancer: Implications for the surveillance strategy. 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
70. Campagna M, Taketa T, Correa AM, Sudo K, Blum MA, Wadhwa R, Komaki R, Lee JH, Bhutani MS, Weston B, Liao ZX, Rice DC, Swisher S, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX. Association of relapse in patients with esophageal and esophagogastric junction (E-EGJ) cancer with surgical stage after trimodality therapy (TMT): Implications for customized surveillance. 2013 Gastrointestinal Symposium, 2013. e-Pub 2013.
71. Sudo K, Taketa T, Correa AM, Campagna M, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Liao ZX, Rice DC, Swisher S, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX. Association of trimodality therapy (TMT) with rate of local-regional relapse and rare luminal-only relapse for patients with esophageal and esophagogastric junction (E-EGJ) cancer: Implications for the surveillance strategy. 2013 Gastrointestinal Cancers Symposium, 2013. e-Pub 2013.
72. Wadhwa R, Xiao L, Sudo K, Taketa T, Blum MA, Skinner HD, Lee JH, Bhutani MS, Weston B, Komaki R, Rice DC, Swisher S, Hofstetter WL, Ajani JA, Cancer Center TUOTMA, Houston, TX. Frequency of relapse over time based on baseline stage in esophageal cancer patients treatment with definitive chemoradiation (DCRT). 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
73. Taketa T, Correa AM, Suzuki A, Blum MA, Lee JE, Welsh J, Lin SH, Maru D, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Swisher S, Wayne Lewis Hofstetter WL, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer (EC) patients who declined surgery after preoperative chemoradiation. J Clin Oncol 4(6), 2012. e-Pub 2012.
74. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh J, Lin SH, Lee JH, Bhutani MS, Weston B, Maru D, Rice DC, Hofstetter WL, Erasmus JJ, Swisher S, Ajani JA. Nomograms for prognostication of patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. J Clin Oncol 4(82), 2012. e-Pub 2012.
75. Blum MA, Hayashi Y, Xiao L, Suzuki A, Sabloff B, Maru DM, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Swisher S, Ajani JA, Cancer Center UOTMDA, Houston, TX. A normogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer (EC). 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
76. Amini A, Welsh J, Allen P, Xiao L, Suzuki A, Blum MA, Hofstetter WL, Liao ZX, Lee JH, Bhutani MS, Komaki R, Cancer Center UOTMDA, Houston, TX, of Medicine UOCIS, Village W, CA, Cancer Center UOTMDA, Houston, TX. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
77. Taketa T, Correa AM, Suzuki A, Blum MA, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Swisher S, Hofstetter WL, Ajani JA, Cancer Center UOTMDA, Houston, TX. Outcome of 58 trimodality-eligible esophagogastric cancer (EC) patients who achieved clinical complete response (cCR) after preoperative chemoradaition but then declined surgery. 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
78. Suzuki A, Xiao L, Taketa T, Blum MA, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Rice DC, Mehran RJ, Maru DM, Erasmus JJ, Hofstetter WL, Swisher S, Ajani JA, Cancer Center UOTMDA, Houston, TX. Customization of treatment for patients with esophageal adenocarcinoma (EAC) who achieve clinical complete response (cCR) after chemoradiation using initial standardized uptake value (iSUV) of 18 f-fluorodeoxyglucose PET. 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
79. Sucharita Cheedella NK, Suzuki A, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Maru DM, Vaporciyan AA, Taketa T, Blum MA, Welsh J, Lin SH, Lee JH, Bhutani MS, Weston B, Walsh GL, Swisher S, Ajani JA, Cancer Center UOTMDA, Houston, TX. Association of clinical complete response (cCR) after preoperative chemoradiation and pathological complete response (pathCR) in patients with gastroesophageal cancer (GEC) and indispensability of trimodality therapy. 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
80. Paraskos LM, Blum MA, Escalon M, Ferrell A, Kobetz E, Rosenblatt AJ. Defining Outcomes in Hispanic Aggressive Non-Hodgkin Lymphoma Patients. Blood 114(4542), 2009. e-Pub 2009.

Book Chapters

1. Murphy B, MA. Gastric, Gastroesophageal and Esophageal Cancer. In: The MD Anderson Manual of Medical Oncology. fourth edition, 2022.
2. Abdelhakeem A, Blum Murphy M. Adjuvant Therapies for Esophageal Cancer. In: Thorac Surg Clin. 4, 457-465, 2022.
3. Karp DD, Gerald S Falchook MD, MS, Lim JD. Esophageal and Gastric Cancer Chapter. In: Handbook of Targeted Cancer Therapy and Immunotherapy. 3rd edition. Wolters Kluwer, 2022.
4. Blum M, and Lynch G. Neuroendocrine Tumors. In: Tumor Board Review: Guidelines and Case Reviews in Clinical Oncology, 2011.

Letters to the Editor

1. Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol 29: 2732; author reply 2732-3, 2011.